# Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

> **NCT00546871** · PHASE2,PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 49 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human), 10%

## Key facts

- **NCT ID:** NCT00546871
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-03
- **Primary completion:** 2009-07-01
- **Final completion:** 2009-09-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546871, "Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00546871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*